$ABCL News

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading

AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares

Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes - Slideshow

AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study

Market-Moving News for August 10th

AbCellera Reports Phase 2 Trial Results Showing Significant Symptom Reduction, Improved Sleep, And Favorable Tolerability For ABCL635

12 Health Care Stocks Moving In Friday's After-Market Session

AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10

Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9

Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation

AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript

AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS

AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate

Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target

Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet